100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
641571-15-5Nilotinib Regio Isomer Impurity
● In Stock
| Catalogue No.: | VE006282 |
|---|---|
| CAS No.: | 641571-15-5 |
| Mol. Formula: | C28H22F3N7O |
| Mol. Weight: | 529.52 g/mol |
Additional information on CAS 641571-15-5
Parent drug
NilotinibIUPAC Name
4-Methyl-N-(3-(5-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamideSynonyms
Nilotinib Impurity H; 4-Methyl-N-(3-(5-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamideSmiles
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=NC=C3C)NC4=NC=CC(=N4)C5=CN=CC=C5Description
Nilotinib EP Impurity H, also designated Nilotinib Regio Isomer Impurity, is a positional isomer of the pyrimidyl-substituted kinase inhibitor nilotinib, associated with alternative arylation or cyclization pathways during synthetic manufacture. It is not a simple degradant but a structurally related process impurity requiring orthogonal identification. CAS 641571-15-5 corresponds to C28H22F3N7O, molecular weight 529.52 g/mol. Because regioisomeric impurities may co-elute with the parent in conventional HPLC, characterization commonly relies on LC-MS/MS, high-resolution MS, and NMR confirmation. Its presence is controlled under impurity specification frameworks, with attention to assignment, reporting thresholds, and potential toxicological qualification.References
Kondra, S. B., et al. “A Validated Stability-Indicative UPLC Method for Nilotinib Hydrochloride for the Determination of Process-Related and Degradation Impurities.” Journal of Chromatographic Science, vol. 52, no. 8, Sept. 2013, pp. 880–85, https://doi.org/10.1093/chromsci/bmt134 Hughes, Timothy, et al. “Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase.” Journal of Clinical Oncology, vol. 27, no. 25, Sept. 2009, pp. 4204–10Request a Quote
"*" indicates required fields
Other products related to Nilotinib impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Nilotinib
CAS No. 641571-06-4
Cat No. VE0020989
![3-{2-[(2-methyl-5-{[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]carbamoyl}phenyl)(nitroso)amino]pyrimidin-4-yl}pyridin-1-ium-1-olate](https://veeprho.com/wp-content/uploads/2024/11/VE0022222-3-2-2-methyl-5-3-4-methyl-1H-imidazol-1-yl-5-trifluoromethyl-phenyl-carbamoyl-phenyl-nitroso-amino-pyrimidin-4-yl-pyridin-1-ium-1-olate.png "3-{2-[(2-methyl-5-{[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]carbamoyl}phenyl)(nitroso)amino]pyrimidin-4-yl}pyridin-1-ium-1-olate")
Nilotinib
CAS No. N/A
Cat No. VE0022222
Nilotinib
CAS No. N/A
Cat No. VE0020002
